Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart

By Saumya Sharma, J. Adrogue, L. Golfman, I. Uray, J. Lemm, K. Youker, G. Noon, O. Frazier, Heinrich Taegtmeyer. The FASEB Journal, 2004

839 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Molecular Biology, Physiology

View Paper: https://www.semanticscholar.org/paper/f4804d4448fe172d33c996d74509478f544f88ab

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. E. Dale Abel
2. Ralph DeFronzo
3. F. Giordano

In Molecular Biology

1. E. Dale Abel
2. Ralph DeFronzo
3. J. Luiken
4. S. Summers
5. F. Giordano
6. A. Bonen
7. William L. Holland
8. J. Glatz

In Physiology

1. Jamal Naderi
2. M. Longo
3. Ralph DeFronzo
4. J. Luiken
5. C. Miele
6. S. Summers
7. F. Giordano
8. A. Bonen

Citations in the corpus

• Cardiac Metabolism in Heart Failure - Implications beyond ATP production (2013, neutral): “In addition, models of HF have been associated with myocardial lipid accumulation.(99,100) As a result, FA use has been considered unfavorable for the stressed heart because of increasing ROS production.”
• Oxygen, oxidative stress, hypoxia, and heart failure. (2005, background): “Lipotoxicity and ROS Myocardial lipotoxicity refers to the accumulation of intramyocardial lipids concomitant with contractile dysfunction, often associated with myocyte death (87, 88).”
• Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 (2010, background): “Myocardial lipid content is increased in type 2 diabetic individuals [197, 198] and contributes to diastolic dysfunction [198, 199].”
• Diabetic cardiomyopathy, causes and effects (2010, background): “In humans with Type 2 diabetes and heart failure, myocardial lipotoxicity was associated with evidence of activation of the PPAR alpha target gene carnitine palmitoyl-transferase 1 (muscle isoform, mCPT1), which regulates mitochondrial FA uptake [19].”
• Age-related changes in total and regional fat distribution. (2009, positive): “…production of reactive oxygen species (i.e. iNOS), ceramides and/or activation of other pathways that lead to cardiac remodeling (i.e. Left ventricular hypertrophy) or decreased contractility due to apoptosis of the cardiomyocyte (Szczepaniak et al., 2003; Sharma et al., 2004; Unger, 2005).”
• Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. (2008, background): “Lipid accumulation in the heart is associated with impaired contractile function (166, 274).”
• Cardiac remodeling in obesity. (2008, background): “Many animal studies have demonstrated this, and recent studies in humans using either NMR spectroscopy or lipid staining of postmortem tissue have provided strong evidence for the existence of lipid accumulation in human hearts (228, 316, 336).”
• Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications (2019, background): “Ectopic lipid deposition in the heart results in a form of “cardiac lipotoxicity” characterized by cardiac IR, apoptosis of the cardiac myocytes, and contractile dysfunction [162,163].”
• Membrane fatty acid transporters as regulators of lipid metabolism: implications for metabolic disease. (2010, background): “However, these processes are unbalanced toward lipid accumulation in insulin-resistant skeletal muscle (18, 48, 164) and the heart (322, 380).”